https://www.neuro-oncology-excellence.com/home daily 1.0 2022-05-11 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/07ab8eaa-dcf0-42c0-a9a7-fe2024ba1b36/hands Home https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/e88e34d9-1be0-4515-a4ba-3efaa8caed18/disease+obstacles Home Brain Cancer Disease Obstacles https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645526465382-IH4KRHYCZE7OAVS4PILM/Zarnie_Lwin_landing_page.jpg Home https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645526956734-ZCHIKBXM1T9F0SZSF9LY/Landing_Page_large.png Home https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645750113486-T28P7QVWXF2A3XPL0KUW/Multi_Disciplinary_extended.jpg Home https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646615518498-66YJM5EG9YTMYNYMFBNJ/Untitled%25252Bdesign%25252B%252525287%25252529.jpg Home https://www.neuro-oncology-excellence.com/mission daily 0.75 2022-03-18 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646111026161-YOP9HAMTGCFL9JEPBMGW/16.png Mission https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646111071677-H46VIY44OX7CZ6FN2KN3/18.png Mission https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646111184499-ZNSX8Z0R1X3WUILZKO47/Untitled+design.png Mission https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646111203997-YU1NQ5MAT5EHP1ZLX72Y/Untitled+design+%281%29.png Mission https://www.neuro-oncology-excellence.com/members daily 0.75 2022-11-22 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645436871485-3BZP399G7N521FHMYJFP/Zarnie_Lwin.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645436903257-JQWOGIMO5LP9PKK5FWUR/Hamish_Alexander.png Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645675989670-CR5CQ868MNX19APR45PL/Lindy_Jeffree.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645676044962-KD5BKDJL2OMWO89OYZM6/Mark_Pinkham.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645753759450-OFIYL3N5OBV26DSZX5F8/Rajiv_Khanna_Headshot_website.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1645753962695-XUTG1YO0LHBJUXXCHKRY/Kris_Thurecht.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646262332700-K80SNYXJMC745QJBS7HR/Sarah_Olson.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646274069391-0ZUAXRV3Z7H6DZQD1VPT/Ben_Chua.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646274434492-Z3I7H8IHHFKH5UXKFUF2/Sunil_Lakhani.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646288085560-U3PFS8XKHQ27TK8IZ99W/TR.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646288145444-PXBBB39FDTJYH2Z34SOJ/Chamindie_Punyadeera.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1646288274464-4FEICPD7DWOV6XQVL9BF/Nic_Waddell.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1647923308794-SBIVG27MELMSATXEYXA3/Po+Inglis.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/1652843378553-CMLGMDW32SR769619NJB/1T0A1778.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/badf98a7-0ae9-4d11-9c2a-4a61883aa8ca/Katharine.jpg Members https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/d94623f6-13ee-4bfa-8667-0aa8567c7af6/image.png Members https://www.neuro-oncology-excellence.com/clinical-trials daily 0.75 2022-03-18 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/752ef77b-6e87-43a3-8e58-689872845322/3.png Clinical Trials - Coming Soon. We are busy working on exciting new research projects and clinical trials. In the meantime, please email bryan.day@qimrberghofer.edu.au with any specific queries. https://www.neuro-oncology-excellence.com/research-streams daily 0.75 2022-03-22 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/f3f01e49-fbb1-4472-ac22-70dab94eba67/research+streams Research Streams - Make it stand out CNE Research Streams https://www.neuro-oncology-excellence.com/bryan-day daily 0.75 2022-05-18 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/2e19951f-91f9-4ef1-bff2-4b66bb32b0d9/1T0A1778.jpg Bryan Day - Prof Bryan Day CNE Chair | Management Committee Prof Day is the Group Leader of the Sid Faithfull Brain Cancer Research Laboratory at QIMR Berghofer MRI and an internationally recognised expert in brain cancer. The focus of his laboratory's research is to better understand the molecular mechanisms which drive the most common and aggressive forms of both adult and paediatric brain cancers. Among Prof Day’s achievements is the characterisation of the receptor EphA3 as a therapeutic target in glioblastoma. This research has led to clinical testing of a novel EphA3 targeting therapeutic antibody in patients with recurrent brain cancer. A major achievement has been the development a brain tumour and cell culture bank at QIMR Berghofer which has collected >350 tumour specimen’s to-date. From this resource >60 primary cell lines have been generated which are the basis of his group's research and collaborative researchers around the world. Twelve of these models have been characterised in great detail and made publicly available as a resource termed QCell. QCell models have been used in numerous studies globally and have been published in >50 articles to-date. Prof Day has >2,000 career citations and has published >60 scientific articles directly relating to understanding the biology of brain cancer and defining new therapies to treat these aggressive diseases. Prof Day is a Co-Director of the Children’s Hospital Foundation, Children’s Brain Cancer Centre (CBCC) and Deputy Chair of the Cooperative Trials Group for Neuro-Oncology (COGNO) scientific advisory board. He sits on the Steering Committee for Brain Cancer Biobanking Australia (BCBA) and is the Brain Tumour Stream Lead – for the MRFF funded Centre for Personalised Analysis of Cancer (CPAC). He is a past Director for the Australian Society of Medical Research (ASMR) and holds adjunct professorial titles from The University of Queensland and QLD University of Technology (QUT). https://www.neuro-oncology-excellence.com/hamish-alexander daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/f94bd06f-9072-419b-8cd8-e8714f7e8a60/Hamish_Alexander.png Hamish Alexander - Dr Hamish Alexander CNE Management Committee Dr Hamish Alexander is Neurosurgeon and Spine Surgeon based in Brisbane, Australia. Dr Alexander is a Consultant Neurosurgeon in the Kenneth G Jamieson Neurosurgery Department, Royal Brisbane and Women’s Hospital and in private practice with BrizBrain & Spine. He is a senior lecturer in the Department of Medicine, University of Queensland and a clinical associate with the Sid Faithful Brain Cancer Laboratory, QIMR Berghofer. Dr Alexander completed his specialist neurosurgical training in New Zealand and Australia having earned undergraduate degrees in neuroscience and medicine at Otago University, NZ. He attained Fellowship of the Royal Australasian College of Surgeons in 2016 Neuro-oncology is a key focus of Dr Alexander’s clinical and research work. He was awarded an M.Phil degree from the University of Queensland in 2015 for research on Immunotherapy for Glioblastoma and subsequently undertook a neurosurgical-oncology fellowship at Memorial Sloan-Kettering Cancer Centre in New York, USA in 2016-17. Dr Alexander also has keen interests in neurotrauma, bio-fabrication and skull base/pituitary surgery. https://www.neuro-oncology-excellence.com/zarnie-lwin daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/b01cf936-2112-40a1-a666-6f48b3d31f24/Zarnie_Lwin.jpg Zarnie Lwin - A/Prof Zarnie Lwin CNE Management Committee A/Prof Lwin (MBBS, FCP, FRACP) is a senior clinician at the Royal Brisbane and Women’s Hospital and University of Queensland. She graduated in Medicine from Burma, completed her FRACP in South Africa, before specializing in Medical Oncology in Australia. She undertook a two-year clinical research fellowship in Princess Margaret Hospital, Canada and specializes in Neuro-oncology. Her other major research interests are in Health Services Research, Equity, Societal Research and Thoracic Oncology. She is Executive Editor for Neuro-oncology Practice, Co-Chair of the Society of Neuro-oncology International Outreach Committee, Deputy Chair of COGNO International Collaborative Research Subcomittee and incoming Chair of the Asian Society of Neuro-oncology inaugural Education and Outreach Committee. She has been invited as international faculty/speaker to several international conferences and has convened numerous scientific meetings. A/Prof Lwin is a Clinical Fellow at the Sid Faithful Brain Cancer Research Laboratory, QIMR Berghofer MRI. She has been site Principal Investigator for numerous clinical trials and has won three awards for her original research in Societal/Health Services Research. https://www.neuro-oncology-excellence.com/mark-pinkham daily 0.75 2022-03-23 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/6890b8e7-7a2d-48a5-a6c0-ab2a890d7226/Mark_Pinkham.jpg Mark Pinkham - A/Prof Mark Pinkham CNE Management Committee Mark Pinkham BM BCh MA (Hons) (Oxon) FRANZCR is a Radiation Oncologist and fulltime academic clinician working at Princess Alexandra Hospital (PAH), Gamma Knife Centre of Queensland and also ICON Cancer Care in Brisbane. He is Adjunct Professor at Queensland University of Technology (QUT) and Honorary Associate at the NHMRC Clinical Trials Centre (University of Sydney). Following admission as a Fellow to the Royal Australian and New Zealand College of Radiologists (RANZCR) in 2014, he completed a post-graduate fellowship in neuro-oncology and stereotactic radiosurgery (SRS) at the world-renowned Christie Hospital in the UK and was appointed as a Staff Specialist at PAH in 2015. Since then, his clinical practice has involved almost exclusively caring for patients with primary and secondary brain tumours. He is an experienced clinical researcher and current member of the Scientific Advisory Committee within Co-operative Group in Neuro-Oncology (COGNO) and Chair of the CNS Working Party within the Trans Tasmin Radiation Oncology Group (TROG). Since 2015, he has published over 40 peer-reviewed manuscripts and 2 book chapters. His research has focused on technical innovation for the treatment of brain tumours and improving survivorship aspects of clinical care. https://www.neuro-oncology-excellence.com/nic-waddell daily 0.75 2022-03-23 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/761f9ca3-b4ab-4d42-be18-61f39a49cb08/Nic_Waddell.jpg Nic Waddell - Dr Nic Waddell Dr Nic Waddell obtained her PhD in molecular biology from the University of Leicester in the UK. She is head of the Medical Genomics Group and Coordinator of the Cancer Program at QIMR Berghofer Medical Research Institute. Prior to that she has been a post-doctoral researcher at the University of Queensland and QIMR Berghofer. She is a cancer researcher and collaborative bioinformatician who is an expert in the interpretation of next generation sequence data. She played a key role in the Australian International Cancer Genome Consortia (ICGC) projects (PIs Grimmond, Biankin and Bowtell). She identified mutational signatures in pancreatic cancer that are linked to germline variants and treatment response, this work was published in Nature and has been cited over 1000 times. Dr Waddell is a member of the Queensland Genomics Health Alliance (QGHA) where she works with the community advisory group in ELSI areas such as community engagement and the development of guidelines to enable the clinical use of genomics. She is also a co-founder of a precision analytics company, genomiQa, who specialize in whole genome data analysis. Her lab at QIMR Berghofer focuses on the genomics of several cancers including oesophageal, melanoma, mesothelioma and lung cancer. Her program of research also uses bioinformatic approaches to address clinical challenges in these diseases. Dr Waddell has >130 publications of which have been cited >21,000 times (Google Scholar) and her current H-index is 49. She has consistently published in high impact journals including articles in Nature, Nature Genetics and Nature Immunology. Dr Waddell is currently a CI on two Australian NHMRC project grants, an NHMRC Centre of Research Excellence grant, and holds an NHMRC Senior Research Fellowship. https://www.neuro-oncology-excellence.com/sarah-olson daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/a1633d5d-ebdd-42f1-904f-4e1d4ea4e229/Sarah_Olson.jpg Sarah Olson - A/Prof Sarah Olson A/Prof Sarah Olson (MBChB (Otago) FRACS, MPhil) is a neurosurgeon in Brisbane, Australia and the immediate past president of the Neurosurgery Society of Australasia. She was the past supervisor of neurosurgical training at Princess Alexandra Hospital for 10 years. A/Prof Olson is a Surgical Education and Training Board Member for Australasia and member of several subcommittees. She is a functional and oncological neurosurgeon and a member of the gamma knife clinical delivery team. Her interests are functional neurosurgery, trigeminal neuralgia, awake craniotomy, pituitary disorders and Gamma knife treatment of neurosurgical conditions. https://www.neuro-oncology-excellence.com/chamindie-punyadeera daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/77f7805a-7898-4f2f-b14b-6fa7fadd7e72/Chamindie_Punyadeera.jpg Chamindie Punyadeera - Prof Chamindie Punyadeera Prof Chamindie Punyadeera is an inventor and a leader in women in Science Technology Engineering Mathematics and Medicine (STEMM). She has had a hybrid research career working in industry as well as in academia. She has worked at Philips Electronics in the Netherlands and has been instrumental in developing Philips Mini-care I-20 for cardiac disease detection. She has also contributed to the development of an integrated platform to detect nucleic acids (Idylla TM) commercialised by Biocartis NV (Belgium). She is a globally acknowledged pioneer in salivary diagnostics. She leads a world-class saliva and liquid biopsy research laboratory in Australia, > 14 researchers focusing on developing novel salivary technologies to detect heart disease and the application of liquid biopsy to accelerate precision treatment in cancers. Prof Punyadeera has 125 publications, 7 invited book chapters, cited >5300 times with a h-index of 40. She has also produced 16 PCT applications. Her team is also developing prognostic assays to identify patients likely to develop recurrences using circulating tumour cells. Her team has discovered the world-first occult HPV driven throat cancer in an asymptomatic person, laying the scientific foundation to initiate a screening program. More recently, her research led to a USA based company obtaining FDA approval for saliva test for oral and throat cancer. Her intellectual property on salivary protein panel to detect heart failure early is licensed to ESN Cleer. She is the convenor of the inaugural saliva conference in Australasia in 2016, which is now a national conference. She has delivered keynote and invited lecturers both nationally and internationally. She is a grant reviewer for both national and international funding agencies and currently serves on the Editorial Board of the Journal of Oral Oncology, associate editor BMC Genomics and a guest editor to BMC Medical Genomics, Diagnostics and Biomolecules. She is a consultant to Oasis Diagnostics®, USA and FLUIDS iQ™, Montreal, Canada. https://www.neuro-oncology-excellence.com/rajiv-khanna daily 0.75 2022-03-23 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/b87d3871-e0b1-4aa6-80c1-f86c21fb7726/Rajiv_Khanna_Headshot_website.jpg Rajiv Khanna - Prof Rajiv Khanna Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the founding Director/Coordinator of Australian Centre for Vaccine Development (now named as QIMR Berghofer Centre for Immunotherapy and Vaccine Development). He is currently appointed as Senior Scientist at QIMR Berghofer Medical Research Institute and is also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences and was awarded Order of Australia in 2017. He has extensive expertise in immunotherapy clinical trials, herpesvirus immunology and vaccine development. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of transplant recipients and autoimmune diseases. Prof. Khanna has been appointed as a consultant to Atara Biotherapeutics (US), CSL Ltd, Cellestis Ltd and Oxford Immunotech (UK) for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by various national and International organizations for expert advice on developing clinical guidelines and scientific review. https://www.neuro-oncology-excellence.com/kris-thurecht daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/408f94df-cbe8-4d5e-9176-c8a0f72f8ef8/Kris_Thurecht.jpg Kris Thurecht - Prof Kris Thurecht Prof. Kris Thurecht is senior group leader at the Centre for Advanced Imaging and the Australian Institute for Bioengineering, and is the Deputy Director, Imaging Technologies at the Centre for Advanced Imaging. His research focusses on development of nanomedicines, and their application in molecular imaging and therapy. He has a particular interest in radiopharmaceuticals and works extensively with industry to improve this class of therapeutic. His team works across the boundaries of chemistry, biology and imaging science to understand how materials interact with biology, and then use this information to develop new pharmaceuticals. https://www.neuro-oncology-excellence.com/lindy-jeffree daily 0.75 2022-03-28 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/47505d64-ad1e-4027-8157-67af101dd45e/Lindy_Jeffree.jpg Lindy Jeffree - A/Prof Lindy Jeffree A/Prof R. L. (“Lindy”) Jeffree (BMedSci, MBBS, MSc, MHE, FRACS) is a full time public hospital neurosurgeon and former director of the Kenneth G. Jamieson Department of Neurosurgery, Associate Professor in the School of Medicine at the University of Queensland and Clinical Fellow at the QIMR Berghofer Medical Research Institute. She is a general neurosurgeon with particular expertise and interest in neuro-oncology, and a Part II examiner in Neurosurgery for Royal Australasian College of Surgeons. Alongside her clinical load, A/Prof Jeffree has clinical and translational research collaborations in the fields of high-grade glioma, cerebral metastases, cerebral imaging and intensive care for neurotrauma. She has been working with the team at the Sid Faithful Brain Cancer Laboratory for more than ten years, with outcomes such the development of Q-cell, a panel of high quality, well characterised primary brain cancer cell line models for academia and commercial use. Her research expertise is recognised by her involvement in national advisory committees for the Australian Brain Cancer Mission, the Mission for Traumatic Brain Injury Working Group on Acute Care, the Co-Operative trials Group in Neuro-Oncology (COGNO) and Brain Cancer Biobanking Australia (BCBA). In addition to recruiting local patients and collecting clinical specimens, A/Prof Jeffree provides a neurosurgical and clinical perspective on all aspects of the research to ensure that projects are practically achievable and benefit patients. https://www.neuro-oncology-excellence.com/thomas-robertson daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/44c3d8f1-6162-40be-a786-7c9c7065deb5/TR.jpg Thomas Robertson - Dr Thomas Robertson Dr Thomas Robertson is Director of Neuropathology for Pathology Queensland and has specific interest in the genetics, biology and diagnosis of tumours of the central nervous system. Dr Robertson and his team have assisted the Sid Faithfull Brain Cancer Research Laboratory in the development of the brain tumour and cell culture bank at QIMR Berghofer through the provision of pathology reports. https://www.neuro-oncology-excellence.com/contact daily 0.75 2022-03-03 https://www.neuro-oncology-excellence.com/ben-chua daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/4e143285-da3b-470c-9b0c-faf640f11ebb/Ben_Chua.jpg Ben Chua - A/Prof Ben Chua A/Prof Ben Chua is a radiation oncologist at the Royal Brisbane & Women’s Hospital with special interest in neuro-oncology, and has a concurrent appointment as associate professor with the Faculty of Medicine, University of Queensland. A/Prof Chua leads a portfolio of active and completed clinical trials in brain and other cancers, with a focus on translational research and national collaborative studies. He is also a member of the Scientific Advisory Committee of the Cooperative Trials Group for Neuro-Oncology (COGNO). A/Prof Chua is focused on improving patient access to clinical trials as well as to high quality, evidence-based care. https://www.neuro-oncology-excellence.com/sunil-lakhani daily 0.75 2022-03-03 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/be727d35-f600-4fe0-9aa3-bef36ba831d4/Sunil_Lakhani.jpg Sunil Lakhani - Prof Sunil Lakhani Prof Sunil Lakhani is a clinical diagnostic and molecular pathologist. He is the Executive Director of Research and Senior Staff Specialist at Pathology Queensland and Head of the Breast Group, University of Queensland Centre for Clinical Research (UQCCR), Brisbane, Australia. His current interests include lobular carcinoma and its variants, triple negative and metaplastic breast cancer and the mechanisms and therapeutic development of brain metastases. He was Series Editor of the 4th Edition WHO Tumour Classification Monographs and Volume Editor of the WHO 4th Ed Tumours of the Breast (2012). He was Standing Member of the Editorial Board for WHO Blue Books 5th Ed (2017-2020) and is Editor of WHO 5th Ed Tumours of the Breast (2019) He is the recipient of the Distinguished Pathologist Medal, Australasian Division of the International Academy of Pathology and The Distinguished Fellow Award, The Royal College of Pathologists of Australasia. In 2017, he was elected Fellow of the Australian Academy of Health and Medical Sciences. https://www.neuro-oncology-excellence.com/po-inglis daily 0.75 2022-03-23 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/6d323ab2-3bd1-4aa5-9f27-c1dee8aae05d/Po+Inglis.jpg Po Inglis - Dr Po Inglis Dr Po Inglis has a Bachelor of Science obtained Monash University 1994, majoring in molecular biology. Her early research work was funded by Anti-Cancer Foundation Grants. During this time she was mentored by Professor Peter Blumbergs at the Hanson Institute of Cancer and Neurological Diseases. After achieving her FRACP in 2009, and whilst working as a full time specialist, she began collaborating with Professor Andrew Boyd and Professor Bryan Day at QIMR Berghofer MRI in the area of brain tumours. Driven by a motivation to establish translational oncology and a collaboration between the clinic and lab, this has seen the development of KB004 and its role in recurrent GBM early phase clinical trial. Her major clinical streams at the Royal Brisbane and Women’s Hospital (RBWH) include tarte brain tumours and adolescent and young adult rare tumors, she actively engages in national and international clinical trials, and continues to support scientists in their pursuit to make molecular oncologic discoveries and therapeutic strategies. https://www.neuro-oncology-excellence.com/katecuff daily 0.75 2022-11-17 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/16bc602d-1753-4c7f-8848-60efd9c62622/Katharine.jpg Kate Cuff - Dr Kate Cuff Dr Kate Cuff is a Medical Oncologist working full time at the Princess Alexandra Hospital. She completed her post graduate medical degree in Brisbane after an undergraduate degree with honours in molecular genetics through the University of Sydney. She completed her advanced training in Medical Oncology and obtained her FRACP in Brisbane and has been employed as a full-time senior staff specialist in Medical Oncology at the Princess Alexandra Hospital since 2011. Her interests include the management of brain malignancies as well as breast and genitourinary cancers. She has a strong focus on clinical research and has been Principal Investigator for numerous clinical trials run through the Cancer Trials Unit at the PAH with the aim of continually improving outcomes for cancer patients. She actively supports scientists based at the Translational Research Centre on the PAH Campus and has been the clinical lead in a number of investigator initiated early phase research trials. https://www.neuro-oncology-excellence.com/jennieroberts daily 0.75 2022-11-30 https://images.squarespace-cdn.com/content/v1/620c5287de74af4f4b0b9674/faca55b6-8d11-436a-8c69-86831754787b/image.png Jennie Roberts - Dr Jennie Roberts Dr Jennie Roberts is a neuro-radiologist at the Royal Brisbane and Women’s Hospital. She has a particular interest in the radiological appearance of early glioblastomas and has lectured and presented research findings on the topic to many of her colleagues, including at the RANZSNR in 2020. Her other passion is the glymphatic system. Jennie is currently the Director of MRI at the RBWH and an examiner for part 2 candidates. She also presents at the weekly neuro-oncology meeting. She has previously had the role of Director of training for Metro North and remains heavily involved in registrar and medical student teaching.